1. | rjs6316 | |
2. | sdcigc | |
3. | 613672 | |
4. | plingle | |
5. | davilenz |
1. | rjs6316 | |
2. | sdcigc | |
3. | 613672 | |
4. | plingle | |
5. | davilenz |
1. | rjs6316 02/08/2018 Sees Q2 revs of $770-785 vs. $790.90 mln |
2. | 613672 05/03/2018 Needham & Co. cuts price target to $43 from $50 |
3. | rjs6316 01/02/2018 Hologic to Present at the 36th Annual J.P. Morgan Healthcare Conference |
4. | plingle 02/02/2018 agree to this |
5. | rjs6316 08/13/2018 Responds to FDA concerns regarding vaginal rejuvenation procedures using energy-based, will suspend marketing |
6. | plingle 02/08/2018 Beats EPS estimates by $0.05 |
7. | 613672 08/03/2018 Receives FDA clearance for its Group B Streptococcus (GBS) assay on the Panther Fusion system |
8. | 613672 02/26/2018 Hologic Signs Exclusive Agreement with DEXALYTICS(TM) to Offer Groundbreaking Body Composition Analysis Software for Athletes |